Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?
作者信息
Inamura Kentaro, Shigematsu Yasuyuki
机构信息
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
出版信息
J Thorac Dis. 2023 May 30;15(5):2882-2884. doi: 10.21037/jtd-22-1862. Epub 2023 Apr 23.
Abstract
摘要
相似文献
1
Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?基于机器学习对非小细胞肺癌患者标准组织学图像上肿瘤浸润淋巴细胞的评估是否与免疫治疗结果相关？
J Thorac Dis. 2023 May 30;15(5):2882-2884. doi: 10.21037/jtd-22-1862. Epub 2023 Apr 23.
2
Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.CT 放射组学分析预测的肿瘤浸润淋巴细胞富集与接受免疫检查点抑制剂治疗的非小细胞肺癌患者的临床结局相关。
Front Immunol. 2023 Jan 5;13:1038089. doi: 10.3389/fimmu.2022.1038089. eCollection 2022.
3
TCF1PD-1 tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer.TCF1PD-1 肿瘤浸润淋巴细胞预测免疫检查点抑制剂治疗非小细胞肺癌的良好反应和延长生存。
Eur J Cancer. 2022 Oct;174:10-20. doi: 10.1016/j.ejca.2022.07.004. Epub 2022 Aug 12.
4
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.人工智能驱动的肿瘤浸润淋巴细胞空间分析作为非小细胞肺癌免疫检查点抑制的补充生物标志物
J Clin Oncol. 2022 Jun 10;40(17):1916-1928. doi: 10.1200/JCO.21.02010. Epub 2022 Mar 10.
5
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.非小细胞肺癌脑转移患者的免疫治疗。了解脑肿瘤微环境并剖析临床免疫检查点阻断治疗的结果。
Cancer Treat Rev. 2020 Sep;89:102067. doi: 10.1016/j.ctrv.2020.102067. Epub 2020 Jul 7.
6
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.临床风险因素、CAR 指数以及免疫细胞组成变化对接受免疫治疗的非小细胞肺癌患者发生超进展性疾病的影响。
BMC Cancer. 2021 Jan 5;21(1):19. doi: 10.1186/s12885-020-07727-y.
7
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
8
The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.PAK7 突变对非小细胞癌免疫检查点抑制剂治疗的预测价值。
Front Immunol. 2022 Feb 3;13:834142. doi: 10.3389/fimmu.2022.834142. eCollection 2022.
9
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.抗 PD-1/PD-L1 免疫疗法疗效的分子异质性与东亚非小细胞肺癌患者的肿瘤免疫微环境相关。
Cancer Biol Med. 2020 Aug 15;17(3):768-781. doi: 10.20892/j.issn.2095-3941.2020.0121.
10
Efficacy of immune checkpoint inhibitor therapy in patients with fusion-positive non-small-cell lung cancer.免疫检查点抑制剂治疗融合阳性非小细胞肺癌患者的疗效。
Immunotherapy. 2021 Aug;13(11):893-904. doi: 10.2217/imt-2021-0035. Epub 2021 Jun 18.
本文引用的文献
1
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.基于机器学习的标准组织学图像中肿瘤浸润淋巴细胞评估与 NSCLC 患者免疫治疗结局的相关性。
JAMA Oncol. 2023 Jan 1;9(1):51-60. doi: 10.1001/jamaoncol.2022.4933.
2
Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.非小细胞肺癌中程序性死亡配体1拷贝数缺失与程序性死亡配体1肿瘤染色减少及冷免疫表型相关。
J Thorac Oncol. 2022 May;17(5):675-687. doi: 10.1016/j.jtho.2022.01.013. Epub 2022 Feb 4.
3
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.程序性细胞死亡配体 1（PD-L1）在非鳞状非小细胞肺癌中的表达与临床病理和基因组学相关性。
Ann Oncol. 2020 Jun;31(6):807-814. doi: 10.1016/j.annonc.2020.02.017. Epub 2020 Apr 27.
4
Evolution of Metastases in Space and Time under Immune Selection.免疫选择下转移在时空上的演变。
Cell. 2018 Oct 18;175(3):751-765.e16. doi: 10.1016/j.cell.2018.09.018. Epub 2018 Oct 11.
5
Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.肿瘤浸润淋巴细胞的空间结构和排列预测早期非小细胞肺癌复发的可能性。
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. doi: 10.1158/1078-0432.CCR-18-2013. Epub 2018 Sep 10.
6
Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling.肝脏的免疫赦免状态受Toll样受体3信号传导的调控。
J Clin Invest. 2006 Sep;116(9):2456-63. doi: 10.1172/JCI28349.
Zotero 插件